UK backs Opdivo for lung cancer after Bristol-Myers cuts price

LONDON (Reuters) - Bristol-Myers Squibb's immunotherapy drug Opdivo has been recommended for some patients with lung cancer by Britain's healthcare cost watchdog NICE after the drugmaker agreed a discounted price.